Partners MPI Research, inviCRO, and 3D Imaging announce name of new facility for molecular imaging, autoradiography, and animal modeling.
MPI Research, inviCRO, and 3D Imaging announced the name of a new advanced imaging center being built at the MPI Research headquarters in Mattawan, Mich. A joint partnership by the three organizations, the Translational Imaging Center, is the first resource for the drug development community to combine molecular imaging, autoradiography, and animal modeling with an onsite cyclotron, vivarium, and advanced image analytics, the companies report.
When completed in Spring 2014, the Center will have the have the ability to translate preclinical data to clinical data, giving drug developers access to imaging, radiochemistry, and informatics solutions to enable faster, better informeddecisions regarding a drug candidate’s potential, according to a press release.
MPI Research, inviCRO, and 3D Imaging’spartnership on the development and operation of the Translational Imaging Center aims to address increasing demand from pharmaceutical and other Iife- science companies for comprehensive imaging services in one location.
Sponsors will be able to enhance their decision-making process based on evaluating three primary criteria: exposure at the target site, binding to the pharmacological target, and expression of the intended pharmacology. When applied to early and mid-stage development, these imaging solutions answer key questions about drug candidates with just a handful ofstudies. For late-stage developers, molecular imaging in concert with otherdiagnostic processes in nonhuman primate models can define the best dosages for future clinical trials, the companies report.
The 10,000-sq-ft, two-story Translational Imaging Center groundbreaking was held in September 2013 and is scheduled to open in the Spring 2014.
Source: MPI Research
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.